Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Interactive world map

Published byBenedetta Giuliani Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure Interactive world map"— Presentation transcript:

1 Figure Interactive world map
Interactive world map (A) Snapshot of the interactive world map ( displays results for the question of antiepileptic drug (AED) discontinuation after temporal lobectomy; the size of the pie charts is proportional to the number of responses from each country or state. (B) Zoomed snapshot of the interactive map centered on the United States, displaying lack of consensus across the country about the same question. Luca Bartolini Neurol Clin Pract 2016;6: © 2016 American Academy of Neurology

Download ppt "Figure Interactive world map"

Similar presentations

The Construction Chart Book, Page 38, Chart 38a.

The Construction Chart Book, Page 38, Chart 38a.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Where is Greece on a map? Magnifying Glass. Where is Greece on a map? Magnifying Glass.

Where is Greece on a map? Magnifying Glass. Where is Greece on a map? Magnifying Glass.
Hire Toyota Innova in Delhi for Outstation Tour

Hire Toyota Innova in Delhi for Outstation Tour
Figure Flow of funds for a 340B agreement for fingolimod

Figure Flow of funds for a 340B agreement for fingolimod
Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)

Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)
مبررات إدخال الحاسوب في رياض الأطفال

مبررات إدخال الحاسوب في رياض الأطفال
Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.

Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.
S. Kılınç, C. Campbell  Seizure - European Journal of Epilepsy 

S. Kılınç, C. Campbell  Seizure - European Journal of Epilepsy 
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
21twelveinteractive.com/ twitter.com/21twelveI/ facebook.com/21twelveinteractive/ linkedin.com/company/21twelve-interactive/ pinterest.com/21twelveinteractive/

21twelveinteractive.com/ twitter.com/21twelveI/ facebook.com/21twelveinteractive/ linkedin.com/company/21twelve-interactive/ pinterest.com/21twelveinteractive/
Figure 2. Ophthalmologic findings of bialleic AP5Z1 mutations

Figure 2. Ophthalmologic findings of bialleic AP5Z1 mutations
Figure 3 Stroke-related deaths and DALYs by country development status

Figure 3 Stroke-related deaths and DALYs by country development status
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.
Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.
Figure Increase of publications relating to genetics and neurology Pubmed was searched for the following advanced search term: (gene[Text Word]) OR mutation[Text.

Figure Increase of publications relating to genetics and neurology Pubmed was searched for the following advanced search term: (gene[Text Word]) OR mutation[Text.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 3 Stepwise strategy of bioinformatic analysis of sequencing results We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain.

Figure 3 Stepwise strategy of bioinformatic analysis of sequencing results We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain.

Similar presentations

Ads by Google